Novartis’ Sandoz division secures FDA approval for biosimilar Hyrimoz
The approval paves way for the use of Hyrimoz in the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older,
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and milestone payments.